AHA Raises ‘Serious Concerns’ with MedPAC’s Direction on 340B

American Hospital Association logo
AHA officials penned a Medical Economics op-ed on “the truth behind growth of the 340B prescription drug program.”
A major hospital advocacy group recently urged congressional advisers to “carefully consider” the potential negative consequences of any new efforts [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

GSK Announces Refunds for 340B Overcharges

GlaxoSmithKline will refund covered entities that purchased certain formulations of a severe asthma treatment in 2022.
GlaxoSmithKline (GSK) will refund covered entities that purchased certain formulations of a severe asthma treatment medication in the third quarter [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B ESP Updates Claims Submission Policy, Stakeholders Voice Concerns About Compliance

Second Sight Solutions updated 340B ESP's terms of use on Oct. 4.
340B covered entities could soon be required to share new information—including reimbursement amounts, ship to dates and ship to locations—as [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

State Contract Pharmacy Lawsuit Weekly Roundup: AstraZeneca Defends Subpoenas; Updates in Missouri, Mississippi, Maryland

Lawsuits challenging 340B contract pharmacy access laws recently heated up in Missouri, Mississippi and Maryland.
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws this [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Former Pfizer Exec. Slams 340B, Says IRA Will Worsen Program in New Op-Ed 

Kirsten Axelsen, a consultant and former Pfizer executive, cautioned that the 340B program “will be even worse” under the IRA in an Aug. 13 op-ed.
A former Pfizer executive and current biopharmaceutical consultant took aim this week at what she called the “poorly managed” 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

UPDATED: AbbVie Ends Voluntary 340B Discount Pricing for Dozens of Orphan Drugs

AbbVie will no longer offer voluntary 340B pricing on any of its orphan-designated drugs to covered entities subject to such exclusions.
AbbVie will no longer offer voluntary 340B pricing on any of its orphan-designated drugs to rural referral centers (RRC), sole [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Massachusetts’ 340B Contract Pharmacy Access Bill Fails to Move in Formal Session, Stakeholders Remain Hopeful

A contract pharmacy access bill could still pass in Massachusetts despite the end of the formal legislative session.
Although Massachusetts lawmakers left Beacon Hill this month without passing a long-stalled 340B contract pharmacy access bill, provider groups say [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

State Contract Pharmacy Lawsuit Weekly Roundup: AstraZeneca Subpoenas in Arkansas, Mississippi; Minnesota AG’s Defense

Lawsuits challenging 340B contract pharmacy access laws recently heated up in Missouri, Mississippi and Maryland.
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws this [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Private Oncologist Group-Funded Study Highlights 340B Contract Pharmacies’ Links to PBMs

Community Oncology Alliance released a study that tries to connect 340B contract pharmacy relationships to the PBM industry.
More than two-thirds of 340B contract pharmacies are associated with pharmacy benefit managers (PBMs) through either vertical integration or contractual [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Senate Committee Votes to Increase HRSA Funding, Flat Fund OPA and Chides Drug Manufacturers on 340B Restrictions

US Capitol
A Senate Committee recently approved the FY25 Departments of Labor, Health and Human Services, Education and Related Agencies Appropriations Act.
The Senate panel responsible for federal appropriations legislation overwhelmingly passed a bill last week that would increase funding for the [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live